Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | NTRK2 fusion |
Gene Variant Detail | |
Relevant Treatment Approaches | Trk Receptor Inhibitor (Pan) |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
NTRK2 fusion | Advanced Solid Tumor | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | FDA approved - On Companion Diagnostic | Actionable | In a combined analysis of 3 clinical trials (ALKA-372-001, STARTRK-1, STARTRK-2) that supported FDA approval, Rozlytrek (entrectinib) treatment resulted in an objective response rate of 57% (31/54, 4 complete response, 27 partial response) in patients with NTRK1/2/3 fusion-positive advanced solid tumors, with a median duration of response of 10 months (PMID: 31838007; 2012-000148-88, NCT02097810, NCT02568267). | detail... 31838007 |
NTRK2 fusion | Advanced Solid Tumor | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | FDA approved | Actionable | In three trials that supported FDA approval, Vitrakvi (larotrectinib) treatment resulted in an overall response rate of 75% (41/55) in adult and pediatric patients with advanced solid tumors harboring either an NTRK1, NTRK2, or NTRK3 fusion, including 7 patients achieving a complete response and 34 patients achieving a partial response (PMID: 29466156; NCT02122913, NCT02637687, NCT02576431). | detail... 29466156 |
NTRK2 fusion | Advanced Solid Tumor | sensitive | Trk Receptor Inhibitor (Pan) | Repotrectinib | FDA approved | Actionable | In a Phase I/II (TRIDENT-1) trial that supported FDA approval, Augtyro (repotrectinib) treatment resulted in a confirmed objective response rate (cORR) of 58% (23/40), a 12-mo duration of response (DOR) of 86%, and 12-mo progression-free survival (PFS) of 56% in TKI-naive patients with advanced solid tumors harboring NTRK fusions, and a 50% (24/48) cORR, 39% 12-mo DOR, and 22% 12-mo PFS in TKI-pretreated patients (Ann Oncol (2023) 34 (suppl_2): S787-S788; NCT03093116). | detail... detail... |
NTRK2 fusion | colon cancer | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Guideline | Actionable | Vitrakvi (larotrectinib) is included in guidelines for advanced or metastatic colon cancer patients with an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | skin melanoma | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Guideline | Actionable | Vitrakvi (larotrectinib) therapy is included in guidelines for patients with metastatic or unresectable cutaneous melanoma harboring an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | lung non-small cell carcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Guideline | Actionable | Vitrakvi (larotrectinib) is included in guidelines as first-line or subsequent therapy for patients with advanced or metastatic non-small cell lung cancer harboring an NTRK2 fusion (NCCN.org). | detail... |
NTRK2 fusion | pancreatic adenocarcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Guideline | Actionable | Vitrakvi (larotrectinib) is included in guidelines as first-line therapy for pancreatic adenocarcinoma patients harboring an NTRK fusion with locally advanced disease with good (ECOG 0-1) or intermediate (ECOG 2) performance status (PS), as first-line therapy for patients with metastatic disease with good, intermediate (category 2A), or poor (ECOG 3) (category 2B) PS, as subsequent therapy for patients with locally advanced, metastatic, or recurrent disease (NCCN.org). | detail... |
NTRK2 fusion | sarcoma | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Guideline | Actionable | Vitrakvi (larotrectinib) is in guidelines for patients with soft tissue sarcoma with non-specific histology and an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | anaplastic thyroid carcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Guideline | Actionable | Vitrakvi (larotrectinib) is included in guidelines as neoadjuvant or systemic therapy for patients with thyroid gland anaplastic carcinoma harboring an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | papillary thyroid carcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Guideline | Actionable | Rozlytrek (entrectinib) is included in guidelines for patients with papillary thyroid carcinoma harboring an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | follicular thyroid carcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Guideline | Actionable | Rozlytrek (entrectinib) is included in guidelines for patients with follicular thyroid carcinoma harboring an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | lung non-small cell carcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Guideline | Actionable | Rozlytrek (entrectinib) is included in guidelines as first-line or subsequent therapy for patients with advanced or metastatic non-small cell lung cancer harboring an NTRK2 fusion (NCCN.org). | detail... |
NTRK2 fusion | oncocytic carcinoma of the thyroid | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Guideline | Actionable | Rozlytrek (entrectinib) is included in guidelines for patients with thyroid Hurthle cell carcinoma harboring an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | anaplastic thyroid carcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Guideline | Actionable | Rozlytrek (entrectinib) is included in guidelines as neoadjuvant or systemic therapy for patients with thyroid gland anaplastic carcinoma harboring an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | papillary thyroid carcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Guideline | Actionable | Vitrakvi (larotrectinib) is included in guidelines for patients with papillary thyroid carcinoma harboring an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | follicular thyroid carcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Guideline | Actionable | Vitrakvi (larotrectinib) is included in guidelines for patients with follicular thyroid carcinoma harboring an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | oncocytic carcinoma of the thyroid | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Guideline | Actionable | Vitrakvi (larotrectinib) is included in guidelines for patients with thyroid Hurthle cell carcinoma harboring an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | sarcoma | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Guideline | Actionable | Rozlytrek (entrectinib) is in guidelines for patients with soft tissue sarcoma with non-specific histology and an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | salivary gland cancer | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Guideline | Actionable | Rozlytrek (entrectinib) is included in guidelines for patients with NTRK2 fusion-positive salivary gland tumors with distant metastases (NCCN.org). | detail... |
NTRK2 fusion | salivary gland cancer | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Guideline | Actionable | Vitrakvi (larotrectinib) is included in guidelines for patients with NTRK2 fusion-positive salivary gland tumors with distant metastases (NCCN.org). | detail... |
NTRK2 fusion | ovary epithelial cancer | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Guideline | Actionable | Vitrakvi (larotrectinib) is included in guidelines as systemic therapy for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer harboring an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | ovary epithelial cancer | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Guideline | Actionable | Rozlytrek (entrectinib) is included in guidelines as systemic therapy for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer harboring an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | small intestine adenocarcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Guideline | Actionable | Vitrakvi (larotrectinib) is included in guidelines for patients with metastatic small bowel adenocarcinoma with an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | colon cancer | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Guideline | Actionable | Rozlytrek (entrectinib) is included in guidelines for advanced or metastatic colon cancer patients with an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | skin melanoma | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Guideline | Actionable | Rozlytrek (entrectinib) therapy is included in guidelines for patients with metastatic or unresectable cutaneous melanoma harboring an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | esophagus adenocarcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Guideline | Actionable | Vitrakvi (larotrectinib) is included in guidelines as second-line or subsequent therapy for patients with unresectable locally advanced, recurrent, or metastatic esophageal adenocarcinoma with an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | gastroesophageal junction adenocarcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Guideline | Actionable | Vitrakvi (larotrectinib) is included in guidelines as second-line or subsequent therapy for patients with unresectable locally advanced, recurrent, or metastatic gastroesophageal junction adenocarcinoma with an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | esophagus adenocarcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Guideline | Actionable | Rozlytrek (entrectinib) is included in guidelines as second-line or subsequent therapy for patients with unresectable locally advanced, recurrent, or metastatic esophageal adenocarcinoma with an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | gastroesophageal junction adenocarcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Guideline | Actionable | Rozlytrek (entrectinib) is included in guidelines as second-line or subsequent therapy for patients with unresectable locally advanced, recurrent, or metastatic gastroesophageal junction adenocarcinoma with an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | stomach cancer | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Guideline | Actionable | Vitrakvi (larotrectinib) is included in guidelines as second-line or subsequent therapy for patients with unresectable locally advanced, recurrent, or metastatic gastric cancer harboring an NTRK2 fusion (NCCN.org). | detail... |
NTRK2 fusion | stomach cancer | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Guideline | Actionable | Rozlytrek (entrectinib) is included in guidelines as second-line or subsequent therapy for patients with unresectable locally advanced, recurrent, or metastatic gastric cancer harboring an NTRK2 fusion (NCCN.org). | detail... |
NTRK2 fusion | pancreatic adenocarcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Guideline | Actionable | Rozlytrek (entrectinib) is included in guidelines as first-line therapy for pancreatic adenocarcinoma patients harboring an NTRK fusion with locally advanced disease with good (ECOG 0-1) or intermediate (ECOG 2) performance status (PS), as first-line therapy for patients with metastatic disease with good, intermediate (category 2A), or poor (ECOG 3) (category 2B) PS, as subsequent therapy for patients with locally advanced, metastatic, or recurrent disease (NCCN.org). | detail... |
NTRK2 fusion | breast cancer | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Guideline | Actionable | Vitrakvi (larotrectinib) therapy is included in guidelines for patients with recurrent unresectable or stage IV (M1) breast cancer harboring an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | breast cancer | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Guideline | Actionable | Rozlytrek (entrectinib) therapy is included in guidelines for patients with recurrent unresectable or stage IV (M1) breast cancer harboring an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | cervical cancer | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Guideline | Actionable | Vitrakvi (larotrectinib) is included in guidelines as second-line therapy for patients with recurrent or metastatic cervical cancer harboring an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | cervical cancer | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Guideline | Actionable | Rozlytrek (entrectinib) is included in guidelines as second-line therapy for patients with recurrent or metastatic cervical cancer harboring an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | hepatocellular carcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Guideline | Actionable | Vitrakvi (larotrectinib) is included in guidelines as subsequent-line therapy for patients with hepatocellular carcinoma harboring an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | hepatocellular carcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Guideline | Actionable | Rozlytrek (entrectinib) is included in guidelines as subsequent-line therapy for patients with hepatocellular carcinoma harboring an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | gallbladder cancer | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Guideline | Actionable | Vitrakvi (larotrectinib) is included in guidelines as primary and subsequent-line therapy for patients with unresectable or metastatic biliary tract cancer harboring an NTRK fusion, including gallbladder cancer (NCCN.org). | detail... |
NTRK2 fusion | gallbladder cancer | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Guideline | Actionable | Rozlytrek (entrectinib) is included in guidelines as primary and subsequent-line therapy for patients with unresectable or metastatic biliary tract cancer harboring an NTRK fusion, including gallbladder cancer (NCCN.org). | detail... |
NTRK2 fusion | intrahepatic cholangiocarcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Guideline | Actionable | Vitrakvi (larotrectinib) is included in guidelines as primary and subsequent-line therapy for patients with unresectable or metastatic biliary tract cancer harboring an NTRK fusion, including intrahepatic cholangiocarcinoma (NCCN.org). | detail... |
NTRK2 fusion | intrahepatic cholangiocarcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Guideline | Actionable | Rozlytrek (entrectinib) is included in guidelines as primary and subsequent-line therapy for patients with unresectable or metastatic biliary tract cancer harboring an NTRK fusion, including intrahepatic cholangiocarcinoma (NCCN.org). | detail... |
NTRK2 fusion | extrahepatic bile duct carcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Guideline | Actionable | Vitrakvi (larotrectinib) is included in guidelines as primary and subsequent-line therapy for patients with unresectable or metastatic biliary tract cancer harboring an NTRK fusion, including extrahepatic cholangiocarcinoma (NCCN.org). | detail... |
NTRK2 fusion | extrahepatic bile duct carcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Guideline | Actionable | Rozlytrek (entrectinib) is included in guidelines as primary and subsequent-line therapy for patients with unresectable or metastatic biliary tract cancer harboring an NTRK fusion, including extrahepatic cholangiocarcinoma (NCCN.org). | detail... |
NTRK2 fusion | endometrial carcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Guideline | Actionable | Vitrakvi (larotrectinib) is included in guidelines as a second-line or subsequent-line therapy (category 2A) for patients with recurrent endometrial carcinoma harboring an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | uterine corpus sarcoma | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Guideline | Actionable | Vitrakvi (larotrectinib) is included in guidelines as first-line therapy for patients with advanced, recurrent, metastatic, or inoperable uterine sarcoma harboring an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | uterine corpus sarcoma | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Guideline | Actionable | Rozlytrek (entrectinib) is included in guidelines as first-line therapy for patients with advanced, recurrent, metastatic, or inoperable uterine sarcoma harboring an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | endometrial carcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Guideline | Actionable | Rozlytrek (entrectinib) is included in guidelines as a second-line or subsequent-line therapy (category 2A) for patients with recurrent endometrial carcinoma harboring an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | gastrointestinal stromal tumor | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Guideline | Actionable | Vitrakvi (larotrectinib) is included in guidelines as neoadjuvant therapy for patients with resectable disease and as first-line systemic therapy for patients with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring NTRK fusions (NCCN.org). | detail... |
NTRK2 fusion | gastrointestinal stromal tumor | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Guideline | Actionable | Rozlytrek (entrectinib) is included in guidelines as neoadjuvant therapy for patients with resectable disease and as first-line systemic therapy for patients with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring NTRK fusions (NCCN.org). | detail... |
NTRK2 fusion | Erdheim-Chester disease | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Guideline | Actionable | Vitrakvi (larotrectinib) is included in guidelines as first-line or subsequent-line therapy for patients with Erdheim-Chester disease harboring NTRK2 fusions (NCCN.org). | detail... |
NTRK2 fusion | Erdheim-Chester disease | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Guideline | Actionable | Rozlytrek (entrectinib) is included in guidelines as first-line or subsequent-line therapy for patients with Erdheim-Chester disease harboring NTRK2 fusions (NCCN.org). | detail... |
NTRK2 fusion | low grade glioma | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Guideline | Actionable | Vitrakvi (larotrectinib) is included in guidelines for patients with recurrent or progressive low grade glioma harboring an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | low grade glioma | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Guideline | Actionable | Rozlytrek (entrectinib) is included in guidelines for patients with recurrent or progressive low grade glioma harboring an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | glioblastoma | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Guideline | Actionable | Vitrakvi (larotrectinib) is included in guidelines for patients with recurrent glioblastoma harboring an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | glioblastoma | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Guideline | Actionable | Rozlytrek (entrectinib) is included in guidelines for patients with recurrent glioblastoma harboring an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | anaplastic astrocytoma | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Guideline | Actionable | Vitrakvi (larotrectinib) is included in guidelines for patients with recurrent anaplastic gliomas harboring an NTRK fusion, including anaplastic astrocytoma (NCCN.org). | detail... |
NTRK2 fusion | anaplastic astrocytoma | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Guideline | Actionable | Rozlytrek (entrectinib) is included in guidelines for patients with recurrent anaplastic gliomas harboring an NTRK fusion, including anaplastic astrocytoma (NCCN.org). | detail... |
NTRK2 fusion | anaplastic oligodendroglioma | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Guideline | Actionable | Rozlytrek (entrectinib) is included in guidelines for patients with recurrent anaplastic gliomas harboring an NTRK fusion, including anaplastic oligodendroglioma (NCCN.org). | detail... |
NTRK2 fusion | anaplastic oligodendroglioma | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Guideline | Actionable | Vitrakvi (larotrectinib) is included in guidelines for patients with recurrent anaplastic gliomas harboring an NTRK fusion, including anaplastic oligodendroglioma (NCCN.org). | detail... |
NTRK2 fusion | rectum cancer | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Guideline | Actionable | Rozlytrek (entrectinib) is included in guidelines for advanced or metastatic rectal cancer patients with an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | rectum cancer | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Guideline | Actionable | Vitrakvi (larotrectinib) is included in guidelines for advanced or metastatic rectal cancer patients with an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | gastrointestinal stromal tumor | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Guideline | Actionable | Vitrakvi (larotrectinib) is included in guidelines for patients with advanced/metastatic gastrointestinal stromal tumor (GIST) harboring NTRK fusions (PMID: 34560242; ESMO.org). | detail... 34560242 |
NTRK2 fusion | gastrointestinal stromal tumor | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Guideline | Actionable | Rozlytrek (entrectinib) is included in guidelines for patients with advanced/metastatic gastrointestinal stromal tumor (GIST) harboring NTRK fusions (PMID: 34560242; ESMO.org). | detail... 34560242 |
NTRK2 fusion | small intestine adenocarcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Guideline | Actionable | Rozlytrek (entrectinib) is included in guidelines for patients with metastatic small bowel adenocarcinoma with an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | ampulla of Vater adenocarcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Guideline | Actionable | Vitrakvi (larotrectinib) is included in guidelines as first-line or subsequent therapy for patients with metastatic ampullary adenocarcinoma harboring NTRK fusions (NCCN.org). | detail... |
NTRK2 fusion | ampulla of Vater adenocarcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Guideline | Actionable | Rozlytrek (entrectinib) is included in guidelines as first-line or subsequent therapy for patients with metastatic ampullary adenocarcinoma harboring NTRK fusions (NCCN.org). | detail... |
NTRK2 fusion | differentiated high-grade thyroid carcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Guideline | Actionable | Vitrakvi (larotrectinib) is included in guidelines for adult or pediatric patients 12 years or older with metastatic differentiated thyroid gland carcinoma harboring NTRK fusions that have progressed on prior therapies (PMID: 31549998, PMID: 35491008; ESMO.org). | detail... 35491008 31549998 |
NTRK2 fusion | differentiated high-grade thyroid carcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Guideline | Actionable | Rozlytrek (entrectinib) is included in guidelines for adult or pediatric patients 12 years or older with metastatic or unresectable differentiated thyroid gland carcinoma harboring NTRK fusions that have progressed on prior therapies (PMID: 31549998, PMID: 35491008; ESMO.org). | detail... 35491008 31549998 |
NTRK2 fusion | high grade glioma | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Guideline | Actionable | Vitrakvi (larotrectinib) is included in guidelines as adjuvant therapy for pediatric patients with diffuse high-grade gliomas harboring NTRK fusions, or as a preferred regimen for patients with recurrent or progressive disease (NCCN.org). | detail... |
NTRK2 fusion | high grade glioma | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Guideline | Actionable | Rozlytrek (entrectinib) is included in guidelines as adjuvant therapy for pediatric patients with diffuse high-grade gliomas harboring NTRK fusions, or as a preferred regimen for patients with recurrent or progressive disease (NCCN.org). | detail... |
NTRK2 fusion | neuroendocrine tumor | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Guideline | Actionable | Rozlytrek (entrectinib) is included in guidelines for patients with unresectable or metastatic extrapulmonary poorly differentiated neuroendocrine carcinoma, large or small cell carcinoma, or mixed neuroendocrine/non-neuroendocrine neoplasms harboring an NTRK fusion who have progressed on or following prior treatment (NCCN.org). | detail... |
NTRK2 fusion | neuroendocrine tumor | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Guideline | Actionable | Vitrakvi (larotrectinib) is included in guidelines for patients with unresectable or metastatic extrapulmonary poorly differentiated neuroendocrine carcinoma, large or small cell carcinoma, or mixed neuroendocrine/non-neuroendocrine neoplasms harboring an NTRK fusion who have progressed on or following prior treatment (NCCN.org). | detail... |
NTRK2 fusion | mammary analogue secretory carcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Guideline | Actionable | Vitrakvi (larotrectinib) is included in guidelines for patients with recurrent or metastatic salivary gland secretory carcinoma harboring NTRK fusions (PMID: 36567082; ESMO.org). | detail... 36567082 |
NTRK2 fusion | mammary analogue secretory carcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Guideline | Actionable | Rozlytrek (entrectinib) is included in guidelines for patients with recurrent or metastatic salivary gland secretory carcinoma harboring NTRK fusions (PMID: 36567082; ESMO.org). | detail... 36567082 |
NTRK2 fusion | biliary tract cancer | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Guideline | Actionable | Vitrakvi (larotrectinib) is included in guidelines as second or later-line therapy for patients with biliary tract cancer harboring an NTRK fusion (PMID: 39864891; ESMO.org). | detail... 39864891 |
NTRK2 fusion | biliary tract cancer | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Guideline | Actionable | Rozlytrek (entrectinib) is included in guidelines as second or later-line therapy for patients with biliary tract cancer harboring an NTRK fusion (PMID: 39864891; ESMO.org). | detail... 39864891 |
NTRK2 fusion | Cancer of Unknown Primary | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Guideline | Actionable | Vitrakvi (larotrectinib) is included in guidelines for patients with cancer of unknown primary harboring NTRK fusions (PMID: 36563965; ESMO.org). | 36563965 detail... |
NTRK2 fusion | Cancer of Unknown Primary | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Guideline | Actionable | Rozlytrek (entrectinib) is included in guidelines for patients with cancer of unknown primary harboring NTRK fusions (PMID: 36563965; ESMO.org). | detail... 36563965 |
NTRK2 fusion | esophagus squamous cell carcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Guideline | Actionable | Rozlytrek (entrectinib) is included in guidelines as second-line or subsequent therapy for patients with unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma with an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | esophagus squamous cell carcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Guideline | Actionable | Vitrakvi (larotrectinib) is included in guidelines as second-line or subsequent therapy for patients with unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma with an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | colorectal cancer | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Guideline | Actionable | Vitrakvi (larotrectinib) is included in guidelines for patients with metastatic colorectal cancer harboring an NTRK fusion (PMID: 36307056; ESMO.org). | 36307056 detail... |
NTRK2 fusion | colorectal cancer | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Guideline | Actionable | Rozlytrek (entrectinib) is included in guidelines for patients with metastatic colorectal cancer harboring an NTRK fusion (PMID: 36307056; ESMO.org). | detail... 36307056 |
NTRK2 fusion | lung non-small cell carcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Guideline | Actionable | Vitrakvi (larotrectinib) is included in guidelines for patients with metastatic non-small cell lung cancer harboring an NTRK fusion with no satisfactory treatment options (PMID: 36872130; ESMO.org). | detail... 36872130 |
NTRK2 fusion | lung non-small cell carcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Guideline | Actionable | Rozlytrek (entrectinib) is included in guidelines for patients with metastatic non-small cell lung cancer harboring an NTRK fusion with no satisfactory treatment options (PMID: 36872130; ESMO.org). | 36872130 detail... |
NTRK2 fusion | pancreatic cancer | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Guideline | Actionable | Vitrakvi (larotrectinib) is included in guidelines for patients with metastatic pancreatic cancer harboring an NTRK fusion (PMID: 37678671; ESMO.org). | 37678671 detail... |
NTRK2 fusion | pancreatic cancer | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Guideline | Actionable | Rozlytrek (entrectinib) is included in guidelines for patients with metastatic pancreatic cancer harboring an NTRK fusion (PMID: 37678671; ESMO.org). | 37678671 detail... |
NTRK2 fusion | Adenocarcinoma of Unknown Primary | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Guideline | Actionable | Vitrakvi (larotrectinib) is included in guidelines for patients with adenocarcinoma of unknown primary harboring NTRK2 fusions (NCCN.org). | detail... |
NTRK2 fusion | Adenocarcinoma of Unknown Primary | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Guideline | Actionable | Rozlytrek (entrectinib) is included in guidelines for patients with adenocarcinoma of unknown primary harboring NTRK2 fusions (NCCN.org). | detail... |
NTRK2 fusion | Squamous Cell Carcinoma of Unknown Primary | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Guideline | Actionable | Rozlytrek (entrectinib) is included in guidelines for patients with squamous cell carcinoma of unknown primary harboring NTRK2 fusions (NCCN.org). | detail... |
NTRK2 fusion | Squamous Cell Carcinoma of Unknown Primary | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Guideline | Actionable | Vitrakvi (larotrectinib) is included in guidelines for patients with squamous cell carcinoma of unknown primary harboring NTRK2 fusions (NCCN.org). | detail... |
NTRK2 fusion | vaginal carcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Guideline | Actionable | Rozlytrek (entrectinib) is included in guidelines as second-line or subsequent therapy for patients with recurrent or metastatic vaginal squamous cell carcinoma or adenocarcinoma harboring an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | vaginal carcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Guideline | Actionable | Vitrakvi (larotrectinib) is included in guidelines as second-line or subsequent therapy for patients with recurrent or metastatic vaginal squamous cell carcinoma or adenocarcinoma harboring an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | extrahepatic bile duct carcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Repotrectinib | Guideline | Actionable | Augtyro (repotrectinib) is included in guidelines as primary and subsequent-line therapy (category 2A) for patients with unresectable or metastatic biliary tract cancer harboring NTRK fusions, including extrahepatic cholangiocarcinoma (NCCN.org). | detail... |
NTRK2 fusion | intrahepatic cholangiocarcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Repotrectinib | Guideline | Actionable | Augtyro (repotrectinib) is included in guidelines as primary and subsequent-line therapy (category 2A) for patients with unresectable or metastatic biliary tract cancer harboring NTRK fusions, including intrahepatic cholangiocarcinoma (NCCN.org). | detail... |
NTRK2 fusion | gallbladder cancer | sensitive | Trk Receptor Inhibitor (Pan) | Repotrectinib | Guideline | Actionable | Augtyro (repotrectinib) is included in guidelines as primary and subsequent-line therapy (category 2A) for patients with unresectable or metastatic biliary tract cancer harboring NTRK fusions, including gallbladder cancer (NCCN.org) | detail... |
NTRK2 fusion | breast cancer | sensitive | Trk Receptor Inhibitor (Pan) | Repotrectinib | Guideline | Actionable | Augtyro (repotrectinib) is included in guidelines for patients with recurrent unresectable or stage IV (M1) breast cancer harboring an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | colon cancer | sensitive | Trk Receptor Inhibitor (Pan) | Repotrectinib | Guideline | Actionable | Augtyro (repotrectinib) is included in guidelines as second-line or subsequent therapy (category 2A) for patients with advanced or metastatic colon cancer harboring an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | rectum cancer | sensitive | Trk Receptor Inhibitor (Pan) | Repotrectinib | Guideline | Actionable | Augtyro (repotrectinib) is included in guidelines as second-line or subsequent therapy (category 2A) for patients with advanced or metastatic rectal cancer harboring an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | small intestine adenocarcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Repotrectinib | Guideline | Actionable | Augtyro (repotrectinib) is included in guidelines as second-line or subsequent therapy (category 2A) for patients with advanced or metastatic small bowel adenocarcinoma harboring an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | ovary epithelial cancer | sensitive | Trk Receptor Inhibitor (Pan) | Repotrectinib | Guideline | Actionable | Augtyro (repotrectinib) is included in guidelines as systemic therapy for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer harboring an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | hepatocellular carcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Repotrectinib | Guideline | Actionable | Augtyro (repotrectinib) is included in guidelines for patients with hepatocellular carcinoma harboring an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | lung non-small cell carcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Repotrectinib | Guideline | Actionable | Augtyro (repotrectinib) is included in guidelines as first-line or subsequent therapy for patients with advanced or metastatic non-small cell lung cancer harboring an NTRK2 fusion (NCCN.org). | detail... |
NTRK2 fusion | ampulla of Vater adenocarcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Repotrectinib | Guideline | Actionable | Augtyro (repotrectinib) is included in guidelines as first-line or subsequent therapy for patients with metastatic ampullary adenocarcinoma harboring NTRK fusions (NCCN.org). | detail... |
NTRK2 fusion | gastrointestinal stromal tumor | sensitive | Trk Receptor Inhibitor (Pan) | Repotrectinib | Guideline | Actionable | Augtyro (repotrectinib) is included in guidelines as neoadjuvant therapy (category 2B) for patients with resectable disease and as first-line or second-line systemic therapy (category 2A) for patients with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring NTRK fusions (NCCN.org). | detail... |
NTRK2 fusion | Erdheim-Chester disease | sensitive | Trk Receptor Inhibitor (Pan) | Repotrectinib | Guideline | Actionable | Augtyro (repotrectinib) is included in guidelines as first-line or subsequent-line therapy for patients with Erdheim-Chester disease harboring NTRK2 fusions (NCCN.org). | detail... |
NTRK2 fusion | sarcoma | sensitive | Trk Receptor Inhibitor (Pan) | Repotrectinib | Guideline | Actionable | Augtyro (repotrectinib) is included in guidelines as a preferred first-line or subsequent therapy for patients with soft tissue sarcoma with non-specific histology harboring an NTRK2 fusion (NCCN.org). | detail... |
NTRK2 fusion | Squamous Cell Carcinoma of Unknown Primary | sensitive | Trk Receptor Inhibitor (Pan) | Repotrectinib | Guideline | Actionable | Augtyro (repotrectinib) is included in guidelines for patients with squamous cell carcinoma of unknown primary harboring NTRK2 fusions (NCCN.org). | detail... |
NTRK2 fusion | Adenocarcinoma of Unknown Primary | sensitive | Trk Receptor Inhibitor (Pan) | Repotrectinib | Guideline | Actionable | Augtyro (repotrectinib) is included in guidelines for patients with adenocarcinoma of unknown primary harboring NTRK2 fusions (NCCN.org). | detail... |
NTRK2 fusion | pancreatic adenocarcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Repotrectinib | Guideline | Actionable | Augtyro (repotrectinib) is included in guidelines as first-line therapy for pancreatic adenocarcinoma patients harboring an NTRK fusion with locally advanced disease with good (ECOG 0-1) or intermediate (ECOG 2) performance status (PS), or with metastatic disease with good, intermediate (category 2A), or poor (ECOG 3) (category 2B) PS, and as subsequent therapy for patients with locally advanced, metastatic, or recurrent disease with good (category 2A), intermediate, or poor (category 2B) PS (NCCN.org). | detail... |
NTRK2 fusion | gastroesophageal junction adenocarcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Repotrectinib | Guideline | Actionable | Augtyro (repotrectinib) is included in guidelines as second-line or subsequent therapy for patients with unresectable locally advanced, recurrent, or metastatic gastroesophageal junction adenocarcinoma with an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | esophagus adenocarcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Repotrectinib | Guideline | Actionable | Augtyro (repotrectinib) is included in guidelines as second-line or subsequent therapy for patients with unresectable locally advanced, recurrent, or metastatic esophageal adenocarcinoma with an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | esophagus squamous cell carcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Repotrectinib | Guideline | Actionable | Augtyro (repotrectinib) is included in guidelines as second-line or subsequent therapy for patients with unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma with an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | neuroendocrine tumor | sensitive | Trk Receptor Inhibitor (Pan) | Repotrectinib | Guideline | Actionable | Augtyro (repotrectinib) is included in guidelines for patients with unresectable or metastatic extrapulmonary poorly differentiated neuroendocrine carcinoma, large or small cell carcinoma, or mixed neuroendocrine/non-neuroendocrine neoplasms harboring an NTRK fusion who have progressed on a prior NTRK-targeted therapy (NCCN.org). | detail... |
NTRK2 fusion | glioblastoma | sensitive | Trk Receptor Inhibitor (Pan) | Repotrectinib | Guideline | Actionable | Augtyro (repotrectinib) is included in guidelines (category 2B) for patients with recurrent glioblastoma harboring an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | pilocytic astrocytoma | sensitive | Trk Receptor Inhibitor (Pan) | Repotrectinib | Guideline | Actionable | Augtyro (repotrectinib) is included in guidelines (category 2B) for patients with recurrent or progressive circumscribed glioma, including pilocytic astrocytoma, harboring an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | pleomorphic xanthoastrocytoma | sensitive | Trk Receptor Inhibitor (Pan) | Repotrectinib | Guideline | Actionable | Augtyro (repotrectinib) is included in guidelines (category 2B) for patients with recurrent or progressive circumscribed glioma, including pleomorphic xanthoastrocytoma, harboring an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | subependymal giant cell astrocytoma | sensitive | Trk Receptor Inhibitor (Pan) | Repotrectinib | Guideline | Actionable | Augtyro (repotrectinib) is included in guidelines (category 2B) for patients with recurrent or progressive circumscribed glioma, including subependymal giant cell astrocytoma, harboring an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | papillary thyroid carcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Repotrectinib | Guideline | Actionable | Augtyro (repotrectinib) is included in guidelines for patients with advanced or metastatic papillary thyroid carcinoma harboring an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | follicular thyroid carcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Repotrectinib | Guideline | Actionable | Augtyro (repotrectinib) is included in guidelines for patients with advanced or metastatic follicular thyroid carcinoma harboring an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | oncocytic carcinoma of the thyroid | sensitive | Trk Receptor Inhibitor (Pan) | Repotrectinib | Guideline | Actionable | Augtyro (repotrectinib) is included in guidelines for patients with advanced or metastatic thyroid Hurthle cell carcinoma harboring an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | anaplastic thyroid carcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Repotrectinib | Guideline | Actionable | Augtyro (repotrectinib) is included in guidelines as neoadjuvant or systemic therapy for patients with thyroid gland anaplastic carcinoma harboring an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | biliary tract cancer | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Guideline | Actionable | Vitrakvi (larotrectinib) is included in the Pan-Asian Guidelines Adaptation (PAGA) for biliary tract cancer patients harboring NTRK fusions who have progressed on or are intolerant of prior therapies (PMID: 39232586; ESMO.org). | 39232586 detail... |
NTRK2 fusion | biliary tract cancer | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Guideline | Actionable | Rozlytrek (entrectinib) is included in the Pan-Asian Guidelines Adaptation (PAGA) for biliary tract cancer patients harboring NTRK fusions who have progressed on or are intolerant of prior therapies (PMID: 39232586; ESMO.org). | 39232586 detail... |
NTRK2 fusion | stomach cancer | sensitive | Trk Receptor Inhibitor (Pan) | Repotrectinib | Guideline | Actionable | Augtyro (repotrectinib) is included in guidelines as second-line or subsequent therapy for patients with unresectable locally advanced, recurrent, or metastatic gastric cancer harboring an NTRK2 fusion (NCCN.org). | detail... |
NTRK2 fusion | salivary gland cancer | sensitive | Trk Receptor Inhibitor (Pan) | Repotrectinib | Guideline | Actionable | Augtyro (repotrectinib) is included in guidelines for patients with unresectable locally advanced, recurrent, or metastatic salivary gland tumors harboring an NTRK2 fusion (NCCN.org). | detail... |
NTRK2 fusion | vaginal carcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Repotrectinib | Guideline | Actionable | Augtyro (repotrectinib) is included in guidelines as second-line or subsequent therapy for patients with recurrent or metastatic vaginal squamous cell carcinoma or adenocarcinoma harboring an NTRK fusion who are naive to prior NTRK targeted therapy or have progressed on prior NTRK therapy (NCCN.org). | detail... |
NTRK2 fusion | cervical cancer | sensitive | Trk Receptor Inhibitor (Pan) | Repotrectinib | Guideline | Actionable | Augtyro (repotrectinib) is included in guidelines as second-line or subsequent therapy for patients with recurrent or metastatic cervical cancer harboring an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | vulva adenocarcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Guideline | Actionable | Rozlytrek (entrectinib) is included in guidelines as a second-line or subsequent therapy for patients with advanced or recurrent/metastatic vulvar adenocarcinoma harboring an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | vulva squamous cell carcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Guideline | Actionable | Rozlytrek (entrectinib) is included in guidelines as a second-line or subsequent therapy for patients with advanced or recurrent/metastatic vulvar squamous cell carcinoma harboring an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | vulva adenocarcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Guideline | Actionable | Vitrakvi (larotrectinib) is included in guidelines as a second-line or subsequent therapy for patients with advanced or recurrent/metastatic vulvar adenocarcinoma harboring an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | vulva squamous cell carcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Guideline | Actionable | Vitrakvi (larotrectinib) is included in guidelines as a second-line or subsequent therapy for patients with advanced or recurrent/metastatic vulvar squamous cell carcinoma harboring an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | vulva squamous cell carcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Repotrectinib | Guideline | Actionable | Augtyro (repotrectinib) is included in guidelines as a second-line or subsequent therapy for patients with advanced or recurrent/metastatic vulvar squamous cell carcinoma harboring an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | vulva adenocarcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Repotrectinib | Guideline | Actionable | Augtyro (repotrectinib) is included in guidelines as a second-line or subsequent therapy for patients with advanced or recurrent/metastatic vulvar adenocarcinoma harboring an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | high grade glioma | sensitive | Trk Receptor Inhibitor (Pan) | Repotrectinib | Guideline | Actionable | Augtyro (repotrectinib) is included in guidelines as adjuvant therapy for pediatric patients with diffuse high-grade gliomas harboring NTRK fusions, or as a preferred regimen for patients with recurrent or progressive disease (NCCN.org). | detail... |
NTRK2 fusion | endometrial carcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Repotrectinib | Guideline | Actionable | Augtyro (repotrectinib) is included in guidelines as a second-line or subsequent-line therapy for patients with recurrent endometrial carcinoma harboring an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | uterine corpus sarcoma | sensitive | Trk Receptor Inhibitor (Pan) | Repotrectinib | Guideline | Actionable | Augtyro (repotrectinib) is included in guidelines as first-line therapy for patients with advanced, recurrent, metastatic, or inoperable uterine sarcoma harboring an NTRK fusion (NCCN.org). | detail... |
NTRK2 fusion | biliary tract cancer | sensitive | Trk Receptor Inhibitor (Pan) | Repotrectinib | Guideline | Actionable | Augtyro (repotrectinib) is included in guidelines as second or later-line therapy for patients with biliary tract cancer harboring an NTRK fusion (PMID: 39864891; ESMO.org). | 39864891 detail... |
NTRK2 fusion | lung non-small cell carcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Guideline | Actionable | Vitrakvi (larotrectinib) is included in the Pan-Asian Guidelines Adaptation (PAGA) for advanced and metastatic non-small cell lung cancer patients harboring NTRK fusions who have no other treatment options (PMID: 39615406; ESMO.org). | 39615406 detail... |
NTRK2 fusion | lung non-small cell carcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Guideline | Actionable | Rozlytrek (entrectinib) is included in the Pan-Asian Guidelines Adaptation (PAGA) for advanced and metastatic non-small cell lung cancer patients harboring NTRK fusions who have no other treatment options (PMID: 39615406; ESMO.org). | 39615406 detail... |
NTRK2 fusion | central nervous system cancer | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Phase II | Actionable | In two Phase II trials, Vitrakvi (larotrectinib) treatment resulted in an objective response rate of 30% (10/33, 3 complete responses, 7 partial responses) in pediatric and adult patients with primary central nervous system tumors harboring NTRK fusions including high grade (n=19) and low grade (n=8) gliomas, with a 24-week disease control rate of 73% and a 12-month progression-free survival rate of 56% (PMID: 34850167; NCT02637687, NCT02576431). | 34850167 |
NTRK2 fusion | Advanced Solid Tumor | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Phase Ib/II | Actionable | In a Phase I/II trial, Vitrakvi (larotrectinib) treatment resulted in complete response in 26.7% (4/15), partial response in 66.7% (10/15), and stable disease in 6.7% (1/15) of pediatric patients with advanced solid tumors harboring NTRK fusions, and progressive diseases in all 7 patients without NTRK fusions (PMID: 29606586; NCT02637687). | 29606586 |
NTRK2 fusion | lung non-small cell carcinoma | sensitive | Trk Receptor Inhibitor (Pan) | Repotrectinib | Phase Ib/II | Actionable | In a Phase I/II (TRIDENT-1) trial, Augtyro (repotrectinib) treatment resulted in a confirmed objective response rate (cORR) of 62%, a 12-mo duration of response (DOR) of 92%, and 12-mo progression-free survival (PFS) of 64% in TKI-naive (n=21) patients with non-small cell lung cancer harboring NTRK fusions, and a 42% cORR, 44% 12-mo DOR, and 23% 12-mo PFS in TKI-pretreated (n=14) patients (Ann Oncol (2023) 34 (suppl_2): S787-S788; NCT03093116). | detail... |
NTRK2 fusion | Advanced Solid Tumor | predicted - sensitive | Trk Receptor Inhibitor (Pan) | Selitrectinib | Phase I | Actionable | In a Phase I trial, Selitrectinib (LOXO-195) treatment resulted in an objective response rate of 34% (10/29) and stable disease in 31% (9/29) of adult and pediatric patients with advanced solid tumors harboring NTRK fusions and had progressed or were intolerant to prior Trk inhibitors (AACR Annual Meeting 2019, Abstract CT127; NCT03215511). | detail... |
NTRK2 fusion | Advanced Solid Tumor | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Clinical Study - Cohort | Actionable | In a combined analysis of three trials, Vitrakvi (larotrectinib) resulted in improved median overall survival (39.7 vs 10.2 months) and a 78% lower risk of death (HR=0.22, P=0.001) compared to standard of care treatment in patients with advanced solid tumors harboring NTRK fusions (PMID: 36689698; NCT02122913, NCT02637687, and NCT02576431). | 36689698 |
NTRK2 fusion | congenital fibrosarcoma | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Clinical Study - Cohort | Actionable | In a retrospective study (EPI VITRAKVI), Vitrakvi (Larotrectinib) treatment in patients with infantile fibrosarcoma harboring an NTRK fusion resulted in an objective response rate of 90.2%, disease control rate of 100%, and an 80% decreased likelihood of a medical treatment failure event (7.8% vs 35.7%, HR=0.20, P=0.0060) compared to chemotherapy-based treatment (PMID: 38657345; NCT05236257). | 38657345 |
NTRK2 fusion | Advanced Solid Tumor | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Clinical Study - Cohort | Actionable | In a combined analysis of 3 clinical trials (STARTRK-NG, TAPISTRY, STARTRK-2), Rozlytrek (entrectinib) treatment resulted in an objective response rate (ORR) of 72.7% (32/44, 20 complete (CR) and 12 partial (PR) responses) in pediatric patients (median age 4.0 yo) with solid tumors harboring NTRK fusions, with median time to response of 1.86 mo, ORR was 91.7% (22/24, 15 CR, 7 PR) in patients with extracranial solid tumors (PMID: 40086048; NCT02650401, NCT04589845, NCT02568267). | 40086048 |
NTRK2 fusion | central nervous system cancer | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Clinical Study - Cohort | Actionable | In a combined analysis of 3 clinical trials (STARTRK-NG, TAPISTRY, STARTRK-2), Rozlytrek (entrectinib) treatment resulted in an objective response rate (ORR) of 72.7% (32/44, 20 complete (CR) and 12 partial (PR) responses) in pediatric patients (median age 4.0 yo) with solid tumors harboring NTRK fusions, with median time to response of 1.86 mo, ORR was 50.0% (10/20, 5 CR, 5 PR) in patients with CNS tumors (PMID: 40086048; NCT02650401, NCT04589845, NCT02568267). | 40086048 |
NTRK2 fusion | Advanced Solid Tumor | sensitive | Trk Receptor Inhibitor (Pan) | Entrectinib | Case Reports/Case Series | Actionable | In a Phase I/II trial (STARTRK-NG), Rozlytrek (entrectinib) treatment was safe and resulted in an overall response rate (ORR) of 57.7% (15/26, 7 complete responses) with median duration of response and progression-free survival no reached in pediatric patients with CNS or extracranial solid tumors harboring fusions in NTRK1, NTRK2, NTRK3, ROS1, or ALK, ORR was 60% (9/15) in patients harboring fusions in NTRK1/2/3 (PMID: 35395680; NCT02650401). | 35395680 |
NTRK2 fusion | Advanced Solid Tumor | predicted - sensitive | Trk Receptor Inhibitor (Pan) | Zurletrectinib | Case Reports/Case Series | Actionable | In a Phase I trial, Zurletrectinib treatment was well tolerated and resulted in an overall response rate of 66.7% (4/6, all partial responses) and a disease control rate of 100% (6/6) in patients with NTRK fusion-positive advanced solid tumors, including one partial response with a measurable decrease in the brain lesion (J Clin Oncol 40, no. 16_suppl (June 01, 2022) 3106; NCT04685226). | detail... |
NTRK2 fusion | high grade glioma | sensitive | Trk Receptor Inhibitor (Pan) | Larotrectinib | Case Reports/Case Series | Actionable | In a clinical case study, Vitrakvi (Larotrectinib) treatment resulted in an overall response rate of 100% (8/8, 4 complete responses, 3 partial responses, 2 minor responses) in patients with pediatric high-grade glioma harboring NTRK fusions (PMID: 39625867). | 39625867 |
CKB CORE allows for only a limited number of monthly page views for un-registered users. However, registration is free and allows for unlimited browsing of the CKB CORE content.
You have reached the monthly page view limit. For continued free access to CKB CORE, please register below: